10679 related articles for article (PubMed ID: 10935469)
1. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma.
Ramirez RD; D'Atri S; Pagani E; Faraggiana T; Lacal PM; Taylor RS; Shay JW
Neoplasia; 1999 Apr; 1(1):42-9. PubMed ID: 10935469
[TBL] [Abstract][Full Text] [Related]
2. Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
Guttman-Yassky E; Bergman R; Manov L; Sprecher E; Shaefer Y; Kerner H
J Cutan Pathol; 2002 Jul; 29(6):341-6. PubMed ID: 12135464
[TBL] [Abstract][Full Text] [Related]
3. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
4. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
[TBL] [Abstract][Full Text] [Related]
5. Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity.
Miracco C; Margherita De Santi M; Schürfeld K; Santopietro R; Lalinga AV; Fimiani M; Biagioli M; Brogi M; De Felice C; Luzi P; Andreassi L
Br J Dermatol; 2002 Mar; 146(3):399-408. PubMed ID: 11952539
[TBL] [Abstract][Full Text] [Related]
6. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of telomerase activity in cutaneous melanocytic proliferations.
Miracco C; Pacenti L; Santopietro R; Laurini L; Biagioli M; Luzi P
Hum Pathol; 2000 Sep; 31(9):1018-21. PubMed ID: 11014565
[TBL] [Abstract][Full Text] [Related]
8. [Significance of human telomerase RNA expression in situ in malignant melanoma].
Wei Q; Fen S
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(2):107-9. PubMed ID: 11938761
[TBL] [Abstract][Full Text] [Related]
9. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
Kuźbicki L; Sarnecka A; Chwirot BW
Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous regression of cutaneous melanoma in sinclair swine is associated with defective telomerase activity and extensive telomere erosion.
Pathak S; Multani AS; McConkey DJ; Imam AS; Amoss MS
Int J Oncol; 2000 Dec; 17(6):1219-24. PubMed ID: 11078808
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions.
Kuźbicki L; Aładowicz E; Chwirot BW
Melanoma Res; 2006 Oct; 16(5):435-44. PubMed ID: 17013093
[TBL] [Abstract][Full Text] [Related]
12. Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
Magro CM; Abraham RM; Guo R; Li S; Wang X; Proper S; Crowson AN; Mihm M
Eur J Dermatol; 2014; 24(5):594-602. PubMed ID: 25118781
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
[TBL] [Abstract][Full Text] [Related]
14. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Singh RS; Diwan AH; Zhang PS; Prieto VG
J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
[TBL] [Abstract][Full Text] [Related]
15. Telomerase Expression in a Series of Melanocytic Neoplasms.
de Unamuno Bustos B; Sahuquillo Torralba A; Moles Poveda P; Pérez Simó G; Simarro Farinos J; Llavador Ros M; Palanca Suela S; Botella Estrada R
Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):212-219. PubMed ID: 30591199
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Mu XC; Tran TA; Ross JS; Carlson JA
J Cutan Pathol; 2000 May; 27(5):242-8. PubMed ID: 10847549
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
19. In-situ hybridization-based quantification of hTR: a possible biomarker in malignant melanoma.
Vagner J; Steiniche T; Stougaard M
Histopathology; 2015 Apr; 66(5):747-51. PubMed ID: 25601620
[TBL] [Abstract][Full Text] [Related]
20. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
